Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30516335 | 1.00 | HTR6 (0.48) | HTR6TP53PLA2G1BL3MBTL1ATG4B | |
| Hydrochloric Acid SCHEMBL30516381 | 0.99 | HTR6 (0.47) | HTR6TP53PLA2G1BL3MBTL1ATG4B | |
| SCHEMBL30516359 | 0.91 | DRD3 (0.44) | HTR6ALDH1A1CYP2C9DRD2 | |
| SCHEMBL21291614 | 0.91 | DRD3 (0.44) | HTR6ALDH1A1CYP2C9DRD2 | |
| SCHEMBL30516341 | 0.88 | CCR2 (0.46) | HTR6MAPTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL21291615 | 0.88 | CCR2 (0.46) | HTR6MAPTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL21291605 | 0.88 | HTR6 (0.48) | HTR6L3MBTL1MAPTALDH1A1DRD2 | |
| SCHEMBL30516356 | 0.88 | HTR6 (0.48) | HTR6L3MBTL1MAPTALDH1A1DRD2 | |
| SCHEMBL21291624 | 0.87 | HTR6 (0.62) | HTR6PLA2G1BL3MBTL1ATG4BMAOB | |
| SCHEMBL21291618 | 0.87 | SOS1 (0.38) | HTR6TP53MAPTALDH1A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319682-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | ADAMED PHARMA S.A. (PL) | 2025-06-03 | — | — | US | claimed |
| US-20240287056-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS | Adamed Pharma S.A (PL) | 2024-08-29 | — | — | US | claimed |
| CN-112041300-B | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | 阿达梅德制药公司 | 2023-07-28 | — | — | CN | claimed |
| EP-3755688-B1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | ADAMED PHARMA S A (PL) | 2023-06-14 | — | — | EP | claimed |
| US-11034688-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | ADAMED PHARMA S.A. (PL) | 2021-06-15 | — | — | US | claimed |
| CN-112041300-A | Indole and benzimidazole derivatives as dual 5-HT2A and5-HT 6receptor antagonists | 阿达梅德制药公司 | 2020-12-04 | — | — | CN | claimed |
| US-20200377496-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A and 5-HT6 RECEPTOR ANTAGONISTS | ACADIA PHARMACEUTICALS INC. | 2020-12-03 | — | — | US | claimed |
| EP-3530651-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | Adamed sp. z o.o. (PL) | 2019-08-28 | — | — | EP | claimed |
| US-12319682-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | ADAMED PHARMA S.A. (PL) | 2025-06-03 | — | — | US | disclosed |
| US-20240287056-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS | Adamed Pharma S.A (PL) | 2024-08-29 | — | — | US | disclosed |
| US-11981668-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | ADAMED PHARMA S.A. (PL) | 2024-05-14 | — | — | US | disclosed |
| CN-112041300-B | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | 阿达梅德制药公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-3755688-B1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | ADAMED PHARMA S A (PL) | 2023-06-14 | — | — | EP | disclosed |
| EP-3755688-B1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | ADAMED PHARMA S A (PL) | 2023-06-14 | — | — | EP | disclosed |
| CN-112041300-A | Indole and benzimidazole derivatives as dual 5-HT2A and5-HT 6receptor antagonists | 阿达梅德制药公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20200377496-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A and 5-HT6 RECEPTOR ANTAGONISTS | ACADIA PHARMACEUTICALS INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200377496-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A and 5-HT6 RECEPTOR ANTAGONISTS | ACADIA PHARMACEUTICALS INC. | 2020-12-03 | — | — | US | disclosed |
| WO-2019162306-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | ADAMED PHARMA S.A. (PL) | 2019-08-29 | — | — | WO | disclosed |
| EP-3530651-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | Adamed sp. z o.o. (PL) | 2019-08-28 | — | — | EP | disclosed |
| EP-3530651-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | Adamed sp. z o.o. (PL) | 2019-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319682-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | HTR2A, HTR6, HTR2C | HTR6 2/4885TP53 4456/4885PLA2G1B 3080/4885 |
| US-11981668-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | HTR2A, HTR2C, HTR6 | HTR6 3/4885TP53 4187/4885PLA2G1B 3564/4885 |
| US-11034688-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | HTR2A, HTR6, HTR2C | HTR6 2/4885TP53 4456/4885PLA2G1B 3080/4885 |
| US-20240287056-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS | HTR2A, HTR6, HTR2C | HTR6 2/4885TP53 4517/4885PLA2G1B 3177/4885 |
| US-20200377496-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A and 5-HT6 RECEPTOR ANTAGONISTS | HTR2A, HTR6, HTR2C | HTR6 2/4885TP53 4456/4885PLA2G1B 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.